Presenters
Emeritus Professor of Pharmacology and Experimental Medicine
Prof. Thomas Unger, MD, PhD, FESC, FAHA
Course Details
Several guidelines have been released on the management of hypertension. In this webinar, Professor Thomas Unger (Maastricht University, the Netherlands), the lead author of the 2020 ISH guidelines, shared these recommendations and outlined the differences of the ISH guidelines to other international guidelines. He also explained the concepts of essential care and optimal care, the crucial role of renin-angiotensin-aldosterone blockade in optimising patient outcomes, and the growing evidence base supporting angiotensin receptor blockers.
Estimated time of Completion: 26 mins. and 16 secs.
CPD Points: 1 Point
PRC Program No: PROG-2023-59346
Current Guidelines in the Management of Hypertension: Where do ARBs fit in? Course Outline
- Hypertension Global Burden
- Cardiovascular Mortality Risk Doubles with Each 20/10 mmHg Increment in Systolic/Diastolic BP*
- 2020 ISH Global Hypertension Practice Guidelines
- Drug Treatment of Hypertension
- ISH- vs European Guidelines
- ESH/ESC 2018: Core drug-treatment strategy for uncomplicated hypertension
- ISH vs ACC/AHA Guidelines
- RAS-Inhibitors
- RAS in cardiovascular pathology
- ARBs and ACE Inhibitors beyond Blood Pressure Reduction
- ACE-Inhibitors reduce CV events* in CV high-risk and HF patients
- Ang II “Escape“ under ACE-I and Prognosis
- Sartans vs ACE Inhibitors
- Combined therapeutic efficiency and tolerability
- ONTARGET/TRANSCEND added to the CV continuum for sartans in CV high-risk patients
- HOPE study results – primary endpoints
- Telmisartan vs other Sartans
- New indication for Telmisartan (MICARDIS®) 80 mg
PC-PH-104928 / June 2023